ID   MOLM-6
AC   CVCL_2122
SY   MOLM6
DR   BTO; BTO:0004177
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473502
DR   CCLE; MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CGH-DB; 9210-4
DR   Cosmic; 787505
DR   Cosmic; 999769
DR   DSMZ; ACC-611
DR   GEO; GSM887331
DR   GEO; GSM888407
DR   Wikidata; Q54906329
RX   PubMed=7873501;
RX   PubMed=10637496;
RX   PubMed=22460905;
RX   PubMed=30285677;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Doubling time: ~48-72 hours (DSMZ).
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.75%; East Asian, North=75.67%; East Asian, South=23.58%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,13
ST   D16S539: 10,11
ST   D5S818: 10,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_7917 ! MOLM-7
OI   CVCL_7918 ! MOLM-8
OI   CVCL_7919 ! MOLM-9
OI   CVCL_7920 ! MOLM-10
OI   CVCL_7921 ! MOLM-11
OI   CVCL_L075 ! MOLM-12
SX   Male
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 24-05-19; Version: 15
//
RX   PubMed=7873501;
RA   Tsuji-Takayama K., Kamiya T., Nakamura S., Matsuo Y., Adachi T.,
RA   Tsubota T., Imanishi J., Minowada J.;
RT   "Establishment of multiple leukemia cell lines with diverse myeloid
RT   and/or megakaryoblastoid characteristics from a single Ph1 positive
RT   chronic myelogenous leukemia blood sample.";
RL   Hum. Cell 7:167-171(1994).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//